CNS Pharmaceuticals (CNSP) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

CNSP Stock Forecast


CNS Pharmaceuticals stock forecast is as follows: an average price target of $0.50 (represents a 354.55% upside from CNSP’s last price of $0.11) and

CNSP Price Target


CNS Pharmaceuticals Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2024Jason McCarthyMaxim Group$0.50$0.15225.52%354.55%

The latest CNS Pharmaceuticals stock forecast, released on Sep 10, 2024 by Jason McCarthy from Maxim Group, set a price target of $0.50, which represents a 225.52% increase from the stock price at the time of the forecast ($0.15), and a 354.55% increase from CNSP last price ($0.11).

CNS Pharmaceuticals Price Target by Period


1M3M12M
# Anlaysts--1
Avg Price Target--$0.50
Last Closing Price$0.11$0.11$0.11
Upside/Downside-100.00%-100.00%354.55%

In the current month, the average price target of CNS Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CNS Pharmaceuticals's last price of $0.11. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

CNS Pharmaceuticals Financial Forecast


CNS Pharmaceuticals Revenue Forecast

Dec 24Sep 24Jun 24
Revenue---
Avg Forecast---
High Forecast---
Low Forecast---
# Analysts---
Surprise %---

CNS Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CNSP's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

CNS Pharmaceuticals EBITDA Forecast

Dec 24Sep 24Jun 24
# Analysts---
EBITDA---
Avg Forecast---
High Forecast---
Low Forecast---
Surprise %---

undefined analysts predict CNSP's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than CNS Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

CNS Pharmaceuticals Net Income Forecast

Dec 24Sep 24Jun 24
# Analysts---
Net Income---
Avg Forecast$-2.66M$-2.22M$505.68K
High Forecast$-2.66M$-2.22M$505.68K
Low Forecast$-2.66M$-2.22M$505.68K
Surprise %---

CNS Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CNSP's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

CNS Pharmaceuticals SG&A Forecast

Dec 24Sep 24Jun 24
# Analysts---
SG&A---
Avg Forecast---
High Forecast---
Low Forecast---
Surprise %---

CNS Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CNSP last annual SG&A of $NaN (undefined).

CNS Pharmaceuticals EPS Forecast

Dec 24Sep 24Jun 24
# Analysts---
EPS---
Avg Forecast$-0.12$-0.10$1.34
High Forecast$-0.12$-0.10$1.34
Low Forecast$-0.12$-0.10$1.34
Surprise %---

According to undefined Wall Street analysts, CNS Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CNSP previous annual EPS of $NaN (undefined).

CNS Pharmaceuticals Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.52$70.0013361.54%Buy
ELEVElevation Oncology$0.67$9.001243.28%Buy
CNSPCNS Pharmaceuticals$0.11$0.50354.55%
IMMXImmix Biopharma$2.29$7.00205.68%Buy

CNSP Forecast FAQ


Will CNS Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for CNSP stock, the company can go up by 354.55% (from the last price of $0.11 to the average price target of $0.5), up by 354.55% based on the highest stock price target, and up by 354.55% based on the lowest stock price target.

Can CNS Pharmaceuticals stock reach $0?

CNSP's average twelve months analyst stock price target of $0.5 supports the claim that CNS Pharmaceuticals can reach $0 in the near future.

What are CNS Pharmaceuticals's analysts' financial forecasts?

CNSP's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-4.374M (high $-4.374M, low $-4.374M), average SG&A $0 (high $0, low $0), and average EPS is $1.12 (high $1.12, low $1.12).